Skip to content

Alto Neuroscience ANRO Debt-to-assets

Debt-to-assets at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
0.0×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
0.0×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
0.0×
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
0.0×
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
0.3×-0.1×
LBR
LB Pharmaceuticals Inc Common StockLBRX

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,358%
Enterprise value$630.81M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Calculated from Alto Neuroscience’s reported figures.

Based on the most recent quarter.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's debt-to-assets?
Alto Neuroscience (ANRO) reported debt-to-assets of 0.1× in Q1 2026.
How has Alto Neuroscience's debt-to-assets changed year-over-year?
Alto Neuroscience's debt-to-assets decreased by 48.5% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Alto Neuroscience's debt-to-assets?
Over 2 years (2023 to 2025), Alto Neuroscience's debt-to-assets has grown at a 1.0% compound annual growth rate (CAGR), from 0.1× to 0.1×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.